A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 03 Jan 2013 Biomarkers information updated
- 18 Jan 2007 Status changed from initiated to recruiting.
- 28 Oct 2005 New trial record.